【Product for Licensing】siRNA Therapeutics Targeting APP for Alzheimer’s Disease (AD)

A siRNA product targeting APP is an innovative therapeutic approach aimed at treating Alzheimer’s disease (AD) by reducing the production of amyloid-beta precursor protein (APP), with the potential to provide pain relief for over six months with a single injection.

Market Size

The global Alzheimer’s disease market is expected to grow rapidly. According to Data Bridge Market Research, the market size was $5.1 billion in 2022 and is projected to reach $9.73 billion by 2030, with a forecasted CAGR of 8.40% during the period. In the Chinese market, it is estimated that by 2030, the sales of lecanemab in China could exceed 3.9 billion yuan, with about 8.32 million patients receiving treatment, achieving a market share and penetration rate of 10%. The domestic Alzheimer’s disease drug market size is expected to reach tens of billions of scale.

Transactions

A significant deal in the siRNA field is AbbVie’s acquisition of Aliada Therapeutics for $1.4 billion. The company’s main research asset, ALIA-1758, is an anti-amyloid-beta (3pE-Aβ) antibody and is considered a potential best-in-class therapy for Alzheimer’s disease. Additionally, Alnylam Pharmaceuticals partnered with Novartis to use siRNA to inhibit targets discovered by Novartis to treat liver diseases, which could enhance the potential for new drugs to treat a variety of diseases.

Competitive Landscape

The Alzheimer’s disease drug development market is highly competitive, with multinational pharmaceutical companies as the main players. In China, there are few participants in the AD new drug development market, and most are in the clinical phase I. Globally, several companies have quickly followed up with product layouts, with some companies paying attention to opportunities for product technological improvements, such as optimizing delivery, nucleic acid modification, and related technical platforms to enhance siRNA gene silencing efficiency and reduce adverse reactions caused by intrathecal injection. As a leader in the RNAi field, Alnylam has five commercialized products in the siRNA field, with nearly $4 billion in financing. Its siRNA drug ALN-APP recently updated positive data at the Alzheimer’s Association International Conference (AAIC).

If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~